Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Xconomy: Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs
12:00pm, Thursday, 18'th Jun 2020
Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential
US Bancorp DE Purchases 1,818 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
07:24am, Thursday, 18'th Jun 2020
US Bancorp DE grew its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 48.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional inv
3 “Strong Buy” Healthcare Stocks That Should Remain Healthy
11:36pm, Wednesday, 17'th Jun 2020
For those that thought the extreme market volatility was behind us, think again. Last week, another burst of volatility was brought on by concerns about the U.S. economic recovery and a second wave of
Oppenheimer Assigns a Buy Rating on Neurocrine (NBIX) - Markets
08:39pm, Tuesday, 16'th Jun 2020
In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Neurocrine (NBIX – Research Report), with
Analysts' Top Healthcare Picks: Albireo Pharma (ALBO), Monopar Therapeutics Inc (MNPR) - Markets
05:58pm, Tuesday, 16'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma
Neurocrine (NBIX) Gets a Hold Rating from Needham - Markets
05:29pm, Tuesday, 16'th Jun 2020
Needham analyst Alan Carr assigned a Hold rating to Neurocrine (NBIX – Research Report) today. The company’s shares closed last
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis
02:47pm, Tuesday, 16'th Jun 2020
ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
Acadia Files Nuplazid Label Expansion; Analyst Sees 'Significant' Potential
10:00am, Tuesday, 16'th Jun 2020
Acadia Pharmaceuticals Inc. (ACAD) has announced that it has filed a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration
Oppenheimer Issues a Buy Rating on Incyte (INCY) - Markets
04:07pm, Monday, 15'th Jun 2020
In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Incyte (INCY – Research Report), with
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential n
Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Needham - Markets
06:44pm, Friday, 12'th Jun 2020
In a report released today, Alan Carr from Needham assigned a Buy rating to Crispr Therapeutics AG (CRSP – Research
Hedge Funds Are Selling ACADIA Pharmaceuticals Inc. (ACAD)
07:37am, Monday, 08'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Why Is Acadia (ACAD) Down 7.6% Since Last Earnings Report?
03:31pm, Saturday, 06'th Jun 2020
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hedge Funds Are Selling ACADIA Pharmaceuticals Inc. (ACAD)
02:50pm, Saturday, 06'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
01:00pm, Tuesday, 02'nd Jun 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020, at 4:40 p.m. Eastern Time.
